Related Experiment Videos
A non-functioning pancreatic neuroendocrine tumour: a case report
Violetta Rosiek1, Jolanta Kunikowska, Beata Kos-Kudła
1Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, ul. Ceglana 35, Katowice, Poland. vml@wp.pl
Endokrynologia Polska
|March 2, 2012
Summary
Advanced pancreatic neuroendocrine tumors (NET) can be challenging to treat. Somatostatin analogues offer a promising therapeutic option for inoperable NET G1 with metastases.
Area of Science:
- Oncology
- Endocrinology
Background:
- Pancreatic neuroendocrine tumors (NET) are a heterogeneous group of neoplasms.
- Non-functioning NETs present diagnostic and therapeutic challenges, especially when advanced.
Observation:
- A 60-year-old female presented with advanced, inoperable non-functioning pancreatic NET (G1) with liver, lymph node, and mediastinal metastases.
- Diagnosis was confirmed via histopathology after exploratory laparotomy.
Findings:
- Somatostatin receptor scintigraphy was positive, indicating suitability for targeted therapy.
- Treatment with somatostatin analogues and radionuclide therapy led to complete remission of liver metastases and reduced primary tumor size.
Implications:
- Somatostatin analogues represent a promising therapeutic strategy for advanced, inoperable neuroendocrine tumors with low proliferative potential.
- This case highlights the efficacy of somatostatin-based therapies in managing advanced pancreatic NETs.
